Heart failure Drug's hidden effects revealed in new study

NCT ID NCT04498780

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug Sacubitril-Valsartan changes heart function in people with heart failure and reduced pumping ability. Researchers used a non-invasive method to measure heart pressure and volume in 117 participants. The goal is to uncover the mechanisms behind the drug's known benefits, such as fewer hospitalizations and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Sacubitril-Valsartan

What this could lead to

If successful, this could help doctors understand why Sacubitril-Valsartan improves symptoms and survival in heart failure patients.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not change current practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kardiopraxis Schirmer

    Kaiserslautern, Germany

  • University of Leipzig

    Leipzig, Saxony, 04103, Germany